Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | IDO1 | P14902 | 2/20 | 0.43 |
| ▸ | F2 | P00734 | 9/20 | 0.43 |
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
| ▸ | GID4 | Q8IVV7 | 1/20 | 0.42 |
| ▸ | F10 | P00742 | 3/20 | 0.42 |
| ▸ | PRSS1 | P07477 | 3/20 | 0.42 |
| ▸ | PRSS2 | P07478 | 3/20 | 0.42 |
| ▸ | PRSS3 | P35030 | 3/20 | 0.42 |
| ▸ | F12 | P00748 | 2/20 | 0.42 |
| ▸ | F7 | P08709 | 2/20 | 0.42 |
| ▸ | F9 | P00740 | 1/20 | 0.42 |
| ▸ | P2RX7 | Q99572 | 4/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6925738 | 1.00 | ALDH1A1 (0.48) | ALDH1A1IDO1F2HTR2CGID4 | |
| SCHEMBL23997637 | 0.95 | HTR2C (0.50) | ALDH1A1IDO1F2HTR2CGID4 | |
| SCHEMBL6923367 | 0.95 | HTR2C (0.50) | ALDH1A1IDO1F2HTR2CGID4 | |
| SCHEMBL15298963 | 0.94 | ALDH1A1 (0.48) | ALDH1A1IDO1F2HTR2CGID4 | |
| SCHEMBL15298957 | 0.89 | F2 (0.45) | ALDH1A1IDO1F2F10PRSS1 | |
| SCHEMBL15298949 | 0.88 | F2 (0.44) | ALDH1A1IDO1F2F10PRSS1 | |
| SCHEMBL6921863 | 0.87 | HTR2C (0.47) | ALDH1A1IDO1F2HTR2CGID4 | |
| SCHEMBL15298947 | 0.86 | ALDH1A1 (0.49) | ALDH1A1F2F10PRSS1PRSS2 | |
| SCHEMBL15285103 | 0.86 | ALDH1A1 (0.45) | ALDH1A1IDO1F2F10PRSS1 | |
| SCHEMBL23997651 | 0.85 | HTR2C (0.46) | ALDH1A1IDO1F2HTR2CGID4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2922535-B1 | THROMBIN INHIBITORS | MERCK SHARP & DOHME (US) | 2021-11-10 | — | — | EP | disclosed |
| US-9469608-B2 | Thrombin inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-10-18 | — | — | US | disclosed |
| US-20150315141-A1 | Thrombin Inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150315141-A1 | Thrombin Inhibitors | F3, F2, F9 | ALDH1A1 4066/4885IDO1 3149/4885F2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.